lURIE CANCER CENTER AND Northwestern Medicine
EXPERTS TO PRESENT AT ASCO 2022
Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present and discuss leading-edge research in cancer care at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7 at McCormick Place in Chicago and Online.
The theme of this year’s meeting, “Advancing Equitable Cancer Care Through Innovation,” reflects our shared commitment to knowledge-sharing across the global oncology community, and to ensuring that all patients have access to and benefit from the latest advances and high-quality cancer care.
The theme of this year’s meeting, “Advancing Equitable Cancer Care Through Innovation,” reflects our shared commitment to knowledge-sharing across the global oncology community, and to ensuring that all patients have access to and benefit from the latest advances and high-quality cancer care.
|
Session
|
Presenter
*Discussant
|
Date & Time
|
Learn More
|
|
Genitourinary Cancer—Kidney and Bladder
The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214. Abstract: 4502 |
June 3, 2022
2:45pm CDT Arie Crown Theater |
|
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
A phase Ib/II study of sotorasib combined with chemotherapy for second-line treatment of KRAS p. G12C–mutated advanced pancreatic cancer. Abstract: TPS4194 Poster: 162a |
June 4, 2022
8:00am CDT In-Person & Live Stream | Hall A |
|
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sequential pembrolizumab (pembro) and chemotherapy (chemo) in newly diagnosed, early unfavorable, or advanced-stage classical Hodgkin lymphoma (cHL): The phase 2 KEYNOTE-C11 study. Abstract: TPS7584 Poster: 233b |
June 4, 2022
8:00am CDT |
|
Special Sessions: Highlights of the Day Session II
Highlights of the Melanoma / Skin Cancers Track Credits: 1.25 |
June 4, 2022
8:48 - 9:00am CDT In-Person & Live Stream | Hall D1 |
|
Sarcoma
Sarcoma Subtypes or Emerging Biomarkers: Are We Making Progress in Precision Immunotherapy? Credits: 3 |
June 4, 2022
1:51pm CDT In-Person & Live Stream | S406 |
|
Window of Opportunity Clinical Trials in Neuro-oncology
Interrogating the Glioblastoma Tumor Immune Microenvironment Via Window-of-Opportunity Clinical Trials. |
June 4, 2022
3:00 - 4:15pm CDT |
|
Development Therapeutics - Immunotherapy
Microsatellite-stable tumors with high tumor mutational burden in association with tumor response to immune checkpoint inhibitor therapy across solid tumors and correlation with specific oncogenic alterations Abstract: 2634 Poster 289 |
Imran Nizamuddin, MD
|
June 5, 2022
8:00pm CDT In-Person & Live Stream | Hall A |
|
Session: Melanoma / Skin Cancers
|
Session Co-Chair:
Sunandana Chandra, MD |
June 5, 2022
9:45am - 12:45pm CDT In-Person & Live Stream | S100a |
|
Session: Central Nervous System Tumors
|
June 5, 2022
11:30am CDT In-Person & Live Stream | S102 |
|
Central Nervous System Tumors
Repeated opening of the blood-brain barrier with the skull-implantable SonoCloud-9 (SC9) device: Phase 1 trial of nab-paclitaxel and SC9 in recurrent glioblastoma. Abstract: 2016 Poster: 354 Credits: 1.5 |
June 5, 2022
11:30am CDT In-Person & On Demand | S102 |
|
Patient-Centered Outcomes
Early Integration of Palliative Medicine for Locally Advanced and Metastatic Genitourniary Malignancies Credits 1.25 |
June 5, 2022
5:05pm CDT In-Person & On Demand | S100bc |
|
Breast Cancer—Metastatic
EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) +/- dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL). Abstract: TPS1107 Poster: 484a |
June 6, 2022
8:00am CDT |
|
Innovative Immune Approaches in Prostate Cancer: A Case-Based Review of CAR T, BiTEs, and Next-Generation Agents
|
Session Chair and Moderator:
David VanderWeele, MD, PhD |
June 6, 2022
8:00am CDT In-Person & Live Stream | Hall B1 |
|
Central Nervous System Tumors
|
Session Chair:
Roger Stupp, MD |
June 6, 2022
11:30am - 2:30pm CDT In-Person & Live Stream | S406 |
|
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Optimizing Multimodal Therapy for Locoregional Non–Small Cell Lung Cancer Credits: 1.5 |
June 6, 2022
11:52am CDT In-Person & Live Stream | Hall D1 |
|
Melanoma/Skin Cancers
Progression and mortality post-immunotherapy discontinuation among patients with BRAFV600-mutant (BRAF+) metastatic melanoma. Abstract: 9531 Poster: 124 |
June 6, 2022
1:15pm CDT |
|
Health Services Research and Quality Improvement
Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study. Abstract: 6567 Poster: 350 |
June 6, 2022
1:15pm CDT In-Person & Live Stream | Hall A |
|
Health Services Research and Quality Improvement
Association of modifiable factors with financial burden and health literacy among patients with cancer. Abstract: 6573 Poster: 356 |
June 6, 2022
1:15pm CDT In-Person & Live Stream | Hall A |
|
Health Services Research and Quality Improvement
Longitudinal changes in financial burden in patients with colorectal cancer treated with curative intent: Primary results of EAQ162CD. Abstract: 5033 Poster: 218 |
June 6, 2022
1:15pm CDT In-Person & Live Stream | Hall A |
|
Genitourinary Cancer—Prostate, Testicular, and Penile
Epigenetic age acceleration in U.S. testicular cancer survivors. Abstract: 5033 Poster: 217 |
June 6, 2022
1:15pm CDT In-Person & Live Stream | Hall A |
|
Genitourinary Cancer—Prostate, Testicular, and Penile
Candidate surrogate endpoints in advanced prostate cancer: Aggregate meta-analysis of 143 randomized trials. Abstract: 5040 Poster: 224 |
June 6, 2022
1:15pm CDT In-Person & Live Stream | Hall A |
|
June 6, 2022
5:25pm CDT In-Person & Live Stream | Arie Crown Theater |
NORTHWESTERN MEDICINE onCOLOGY
|
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is a global leader in a broad range of cancer types thanks to its dedication to comprehensive research, world-renowned faculty and staff and its commitment to making ongoing advances in medical, surgical, radiation and interventional oncology. The Lurie Cancer Center is designated by the National Cancer Institute as one of only 51 comprehensive cancer in the nation recognized for their scientific leadership, resources and the depth and breadth of their research. In addition, Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN) and our physicians actively participate in writing NCCN patient guidelines for each type cancer.
|